MedPath

Zhejiang Kanova Biopharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 1
1 (33.3%)

A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses

Not Applicable
Completed
Conditions
Asthma Patients
Interventions
Drug: XKH001 Injection
First Posted Date
2025-07-17
Last Posted Date
2025-07-17
Lead Sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Target Recruit Count
12
Registration Number
NCT07070297
Locations
🇨🇳

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Not Applicable
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: XKH001 Injection
Drug: XKH001 Placebo Injection
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Target Recruit Count
120
Registration Number
NCT07054736
Locations
🇨🇳

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Phase I of XKH002 Injection in Patients

Phase 1
Recruiting
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Drug: XKH002 Injection
First Posted Date
2024-01-09
Last Posted Date
2024-10-10
Lead Sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Target Recruit Count
110
Registration Number
NCT06196762
Locations
🇨🇳

Peking University Cancer Hospital, Beijing, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.